| Literature DB >> 23613879 |
Eiryu Sai1, Kazunori Shimada, Takayuki Yokoyama, Shuji Sato, Tetsuro Miyazaki, Makoto Hiki, Yoshifumi Tamura, Shigeki Aoki, Hirotaka Watada, Ryuzo Kawamori, Hiroyuki Daida.
Abstract
Ectopic fat accumulation plays important roles in various metabolic disorders and cardiovascular diseases. Recent studies reported that myocardial triglyceride (TG) content measured by proton magnetic resonance spectroscopy ((1)H-MRS) is associated with aging, diabetes mellitus, and cardiac dysfunction. However, myocardial TG content in athletes has not yet been investigated. We performed (1)H-MRS and cardiac magnetic resonance imaging in 10 male endurance athletes and 15 healthy male controls. Serum markers and other clinical parameters including arterial stiffness were measured. Cardiopulmonary exercise testing was also performed. There were no significant differences in clinical characteristics including age, anthropometric parameters, blood test results, or arterial stiffness between the two groups. Peak oxygen uptakes, end-diastolic volume (EDV), end-systolic volume (ESV), left ventricular (LV) mass, peak ejection rates and peak filling rates were significantly higher in the athlete group than in the control group (all P<0.02). Myocardial TG content was significantly lower in the athlete group than in the control group (0.60 ± 0.20 vs. 0.89 ± 0.41%, P<0.05). Myocardial TG content was negatively correlated with EDV (r = -0.47), ESV (r = -0.64), LV mass (r = -0.44), and epicardial fat volume (r = 0.47) (all P<0.05). In conclusion, lower levels of myocardial TG content were observed in endurance athletes and were associated with morphological changes related to physiological LV alteration in athletes, suggesting that metabolic imaging for measurement of myocardial TG content by (1)H-MRS may be a useful technique for noninvasively assessing the "athlete's heart".Entities:
Mesh:
Substances:
Year: 2013 PMID: 23613879 PMCID: PMC3628784 DOI: 10.1371/journal.pone.0061604
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Representative results of H1-MR spectra in a healthy subject.
A: Myocardial voxel localization for H1-MRS in 4-chamber and short axis views. B: H1-MR spectra without water suppression. C: H1-MR spectra without water suppression.
Clinical Characteristics.
| Control group(n = 15) | Athlete group(n = 10) | P value | |
| Age, years | 28.8±4.5 | 26.4±4.4 | 0.20 |
| Body height, m | 1.735±0.051 | 1.732±0.047 | 0.88 |
| Body weight, kg | 67.9±7.4 | 67.8±4.2 | 0.94 |
| Body mass index, kg/m2 | 22.5±1.9 | 22.6±1.9 | 0.90 |
| Skeletal muscle mass, kg | 30.7±2.6 | 32.5±2.0 | 0.083 |
| Body fat weight, kg | 13.6±3.8 | 10.6±3.6 | 0.066 |
| Percent of body fat, % | 18.6±5.0 | 15.4±4.8 | 0.14 |
| Neck circumference, cm | 36.9±2.4 | 36.8±1.8 | 0.92 |
| Waist circumference, cm | 80.5±6.8 | 78.1±4.0 | 0.36 |
| Total cholesterol, mg/dl | 174.6±26.3 | 182.5±24.5 | 0.45 |
| Triglyceride, mg/dl | 74.6±27.0 | 61.1±15.8 | 0.16 |
| LDL-cholesterol, mg/dl | 104.2±26.4 | 111.1±29.0 | 0.53 |
| HDL-cholesterol, mg/dl | 55.7±11.3 | 59.2±12.7 | 0.47 |
| Fasting free fatty acid, µEq/L | 299.1±132.3 | 364.7±211.5 | 0.32 |
| Fasting blood glucose, mg/dl | 90.7±8.6 | 90.9±5.0 | 0.93 |
| Insulin, µU/ml | 5.6±3.0 | 4.4±1.4 | 0.22 |
| HOMA-IR | 1.3±0.6 | 1.0±0.3 | 0.22 |
| HbA1c, % | 4.7±0.3 | 4.7±0.2 | 0.51 |
| Creatinine, mg/dl | 0.84±0.10 | 0.84±0.05 | 0.85 |
| eGFR, ml/min/m2 | 91.6±12.2 | 92.1±6.7 | 0.91 |
| NT-proBNP, ng/l | 18.6±18.0 | 10.1±3.9 | 0.15 |
| Urinary acid, mg/l | 6.0±0.9 | 5.4±1.3 | 0.15 |
| Anaerobic threshold,ml/kg/min | 19.0±5.2 | 29.2±6.6 | 0.0002 |
| VO2max, ml/kg/min | 43.2±8.0 | 52.3±6.2 | 0.0057 |
| CAVI | 6.5±0.7 | 6.2±0.6 | 0.53 |
| IPAQ score | 2318±1605 | 5310±2869 | 0.0048 |
Values are mean ± SD. bpm = beats per minutes, LDL = low-density lipoprotein; HDL = high-density lipoprotein; eGFR = estimated glomerular filtration rate; HOMA-IR = homeostasis model assessment of insulin resistance, NT-proBNP = N-terminal pro brain natriuretic peptides, VO2max = maximal oxygen intake, CAVI = cardio ankle vascular index, IPAQ = international physical activity questionnaire.
P value denotes significance of unpaired t test between athlete group and healthy control.
MRI variables.
| Control group(n = 15) | Athlete group(n = 10) | P value | |
| LV ejection fraction, % | 50.6±5.5 | 48.1±6.3 | 0.32 |
| LV end diastolic volume, ml | 153±16 | 182±24 | 0.0011 |
| LV end systolic volume, ml | 73±8 | 95±16 | 0.0002 |
| Stroke volume, ml | 80±14 | 88±17 | 0.22 |
| Cardiac output | 4.8±0.8 | 5.2±1.2 | 0.29 |
| LV myocardial mass, g | 120±13 | 139±16 | 0.0034 |
| Peak ejection rate, ml/sec | 551±206 | 777±230 | 0.019 |
| Peak filling rate, ml/sec | 619±177 | 839±250 | 0.018 |
| Epicardial fat volume, ml | 48.8±14.8 | 38.3±8.2 | 0.057 |
Values are mean ± SD. LV = left ventricular.
P value denotes significance of unpaired t test between athlete group and healthy control.
Figure 2Comparison between myocardial TG content in the control group and the athlete group.
* P<0.05 between the two groups.
Figure 3Correlations between myocardial TG content and MRI parameters.
A: A correlation between myocardial TG content and end-diastolic volume. B: A correlation between myocardial TG content and end-systolic volume. C: Correlation between myocardial TG content and left ventricular (LV) mass. D: Correlation between myocardial TG content and epicardial fat volume. Open circle; control group. Closed circle; athlete group.